Amolyt Pharma

Abbisko's PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor
CompanyDrug

Abbisko’s PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor

Abbisko Therapeutics (HKG: 2256) announced that its independently developed small‑molecule colony‑stimulating factor 1 receptor (CSF‑1R) inhibitor, PIMJETMI (pimicotinib hydrochloride capsules), has received approval from the U.S. Food and Drug Administration…

Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL

Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL

Evopoint Biosciences' Imipenem/Cilastatin/Funobactam Wins NMPA Marketing Approval – Class 1 Triple‑Combination Antibiotic for HABP and VABP

Evopoint Biosciences’ Imipenem/Cilastatin/Funobactam Wins NMPA Marketing Approval – Class 1 Triple‑Combination Antibiotic for HABP and VABP

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline